What is CBG? The Mother of Cannabinoids - Action, Receptors, Dosage 2026

If you're looking for answers to the question "What is CBG?" you've stumbled upon one of the most underrated cannabis cannabinoids. Cannabigerol (CBG) typically makes up less than 1 percent of the cannabinoid mass in a mature cannabis plant, yet it's the biochemical precursor to virtually all other cannabinoids, including CBD, THC, and CBC (Calapai et al., Medicina, 2022). The CBG market in Europe is growing at a CAGR of 16.2 percent (Fortune Business Insights, 2024), and the reason is simple. CBG binds directly to CB1 and CB2 receptors as a partial agonist, activates the alpha-2 adrenergic receptor, and shows promising data in chronic inflammation, bacterial resistance, and intestinal pathologies.

In this guide, we explain the biochemistry of CBG, how its receptor profile differs from CBD, the current clinical and preclinical evidence, realistic sublingual doses, Polish and European law, and when to use CBG oil instead of CBD. Without marketing simplification, we offer references to PubMed, PMC, the British Journal of Pharmacology, and Cannabis and Cannabinoid Research.

KEY INFORMATION

Mother of cannabinoids: CBGA is the biochemical precursor of CBDA, THCA and CBCA, without CBGA the remaining plant cannabinoids are not produced (Calapai et al., Medicina, 2022).

Receptor profile: CB1 and CB2 as partial agonist, strong alpha-2 adrenergic activity, 5-HT1A antagonism (Cascio et al., British Journal of Pharmacology 2010).

Sublingual dosage: start 10-15 mg daily, ultimately 25-50 mg in two portions with titration every 5-7 days.

Strongest evidence: antibacterial effect on MRSA (Farha et al., 2020), reduction of intestinal inflammation (Borrelli et al., 2013), reduction of intraocular pressure (Colasanti, 1990).

Legality: CBG is allowed in Poland and the EU, products must have THC below 0.3 percent and a COA certificate.

What is CBG from the perspective of the biochemistry of the cannabis plant?

CBG is a non-psychoactive phytogenic cannabinoid that is formed first in the cannabinoid biosynthesis pathway in the trichomes of the cannabis plant. In its acidic form (CBGA), it acts as a precursor to three main enzymatic pathways: THCA synthase, CBDA synthase, and CBCA synthase (Calapai et al., Medicina, 2022). Less than 1 percent of CBG mass remains in a mature plant, so varieties bred specifically for its extraction are harvested earlier.

The full chemical name of CBG is cannabigerol, and its molecular formula is C21H32O2. Its structure has an open geranyl chain, which distinguishes it from CBD, which has a closed pyran ring. This subtle structural distinction explains CBG's greater lipophilicity and stronger affinity for the alpha-2 adrenergic receptor. In plant synthesis, synthase enzymes are selective: the same CBGA can be converted to THCA in marijuana or to CBDA in hemp.

The biochemical specificity of CBG explains its rarity. Cannabis strains selected over the past two decades for high CBD or THC content had minimal CBG concentrations, as most of the CBGA was consumed by the synthase enzymes. In 2019, the University of Guelph (Canada) introduced strains with 10-15 percent CBG, thanks to a genetic "switch-off" of THCA and CBDA synthase. The commercial CBG market accelerated only after this breeding shift.

Why is CBG called the mother of cannabinoids?

The term "mother of cannabinoids" comes from the fact that CBGA is a common substrate from which other cannabinoid acids are formed. Without CBGA, there are no CBDA, THCA, or CBCA. Upon thermal decarboxylation, all of these acids lose their carboxyl group and are converted into the active, neutral forms: CBD, THC, and CBC. This explains why CBGA is unique in the context of cannabinoid biosynthesis.

In practice, the importance of CBG's maternal role transcends biology. For oil producers, this means that plants must be harvested before the synthase enzymes can consume the CBGA. For consumers, this means that CBG oils are more expensive because the raw material must be obtained more quickly and the yield is lower. The production cost of CBG oil is two to three times higher than that of CBD oil of the same strength.

Chemical structure and physicochemical properties

CBG has a molar mass of 316.48 g/mol and is highly lipophilic (logP ≈ 6.1). This means it dissolves in fats, but not in water. At room temperature, it is a thick, light yellow oil with a delicate, grassy aroma. Its boiling point is 257 degrees Celsius, which is important when vaporizing CBG-rich hemp.

Like CBD and THC, CBG is sensitive to UV light and oxygen. Therefore, high-quality oils are packaged in dark glass bottles and stored in a cool place. Exposure to heat above 60 degrees Celsius accelerates oxidative degradation, which impacts the product's effectiveness once the package is opened.

How does CBG affect CB1, CB2 and alpha-2 receptors?

CBG acts as a partial agonist at CB1 and CB2 receptors and a potent modulator of the alpha-2 adrenergic receptor (Cascio et al., British Journal of Pharmacology, 2010). This fundamentally distinguishes it from CBD, which has minimal direct affinity for CB1 and CB2 and acts primarily through the 5-HT1A receptor and inhibition of the FAAH enzyme. CBG therefore occupies a unique position in the endocannabinoid system.

The CB1 receptor is found primarily in the central nervous system, in the cerebral cortex, hippocampus, and cerebellum. CB1 activation is responsible for the psychoactive effects of THC. However, CBG, as a partial CB1 agonist, does not induce a high because its intrinsic activity is very low. In the presence of THC, CBG actually antagonizes its psychoactive effects, as confirmed by Cascio's 2010 study. Therefore, CBG oils do not cause perceptual disturbances.

The CB2 receptor is found primarily in cells of the immune system, gut, and skin. CB2 activation has anti-inflammatory, analgesic, and immunomodulatory effects. CBG, as a partial CB2 agonist, accounts for its anti-inflammatory effects in models of IBD, acne, and arthritis. This mechanism is complementary to the action of CBD on the same receptor.

Alpha-2 adrenergic receptor, a unique feature of CBG

The alpha-2 adrenergic receptor is found in the presynaptic terminals of noradrenergic neurons. Its activation reduces the release of noradrenaline, which leads to lower blood pressure, smooth muscle relaxation, and a decrease in intraocular pressure. This is the same mechanism used by brimonidine eye drops for glaucoma.

CBG's affinity for alpha-2 adrenergic receptors is significantly higher than that of CBD. The Ki value is approximately 0.2 micromolar for CBG compared to over 10 micromolar for CBD. This difference explains why CBG has a more pronounced effect on concentration, muscle tone, and intraocular pressure. This is not a "stronger" effect, but rather a different pharmacological mechanism.

Modulation of the 5-HT1A receptor and other targets

CBG also affects the 5-HT1A serotonin receptor, but unlike CBD, it acts as an antagonist rather than an agonist. This has significant consequences. CBD increases serotonin transmission (an anxiolytic effect), while CBG may decrease it at high doses. Therefore, higher doses of CBG may induce a state of arousal rather than sedation.

CBG also affects vanilloid receptors TRPV1 and TRPV2 (pain and temperature receptors), TRPA1 receptors, and PPAR-gamma. Activation of PPAR-gamma has anti-inflammatory, metabolic, and neuroprotective effects. This broad map of molecular targets explains why CBG demonstrates activity in such diverse disease models, from glaucoma to inflammatory bowel disease.

Unique observation: While CBD is a "modulating molecule" (it alters the action of existing neurotransmitters), CBG is a "direct-acting molecule" on cannabinoid receptors. This mechanistic difference means that CBG may be more predictable in its effects than CBD, but also more dose-sensitive. Too high a dose of CBG may cause stimulation rather than sedation, which is not observed with CBD.

Citation capsule: In the receptor study by Cascio et al. (2010), CBG showed an affinity of Ki = 0.2 micromolar for the alpha-2 adrenergic receptor, a value comparable to the clinically used brimonidine, while its activity at the CB1 receptor was approximately 100 times weaker than that of THC (British Journal of Pharmacology, 2010). This confirms that CBG does not cause psychoactive effects.

What is the strongest therapeutic evidence for CBG?

The best documented effects of CBG are its antibacterial effect on resistant strains (MRSA), reduction of intestinal inflammation in animal models, and reduction of intraocular pressure. In the study by Farha et al. (ACS Infectious Diseases, 2020) CBG inhibited MRSA growth at concentrations comparable to vancomycin. This is the strongest preclinical data for this cannabinoid.

The study by Borrelli et al. (Biochemical Pharmacology, 2013) showed that CBG reduced colitis in a mouse model of DNBS by approximately 50 percent. The mechanism involves inhibition of iNOS synthase, reduction of IL-1beta, and modulation of CB2. This provides a foundation for further research into the use of CBG in human inflammatory bowel disease.

Colasanti's work (Journal of Ocular Pharmacology, 1990) demonstrated that topically administered CBG lowers intraocular pressure in rabbits. The mechanism is based on activation of the alpha-2 receptor, similar to that of the clinically used drug brimonidine. This is old but still cited evidence for CBG's ophthalmic potential.

Antibacterial activity against resistant strains

In a 2020 study by Farha, CBG was tested against 96 strains of gram-positive and gram-negative bacteria. It demonstrated the best activity against MRSA, with a minimum inhibitory concentration (MIC) of 2 micrograms/ml. For comparison, vancomycin's MIC against MRSA is 1-2 micrograms/ml, indicating comparable potency in vitro.

A unique feature of CBG is its ability to disrupt bacterial biofilm. Biofilm is a protective structure that bacteria form on surfaces (implants, catheters, wounds). Classic antibiotics have difficulty penetrating biofilm. In Farha's study, CBG disrupted MRSA biofilm at concentrations that did not kill free bacteria. This represents a new potential therapeutic approach.

In a mouse model of MRSA infection, systemic CBG reduced the bacterial load by 2-3 orders of magnitude compared to the control group. This suggests that CBG may be considered an adjunct to conventional antibiotic therapy, particularly in skin and soft tissue infections. However, clinical trials in humans are necessary before any therapeutic use.

Potential in inflammatory bowel disease (IBD)

Borrelli's 2013 work is the most frequently cited evidence for CBG's effects in IBD. In a mouse model of DNBS-induced colitis, CBG at a dose of 1-30 mg/kg body weight reduced inflammatory markers by 40-60 percent. The most important effects included a decrease in myeloperoxidase (MPO), a reduction in IL-1beta, and a reduction in histological damage to the mucosa.

Importantly, CBG worked effectively without causing significant side effects in animals. This contrasts with traditional IBD therapy (steroids, immunosuppression), which has numerous side effects. CBG may be considered a complementary therapy in the future, but randomized trials in humans with Crohn's disease and ulcerative colitis are needed.

Glaucoma, IBD, and Neuroprotection: What We Know Now

In glaucoma, CBG demonstrated potential in Colasanti's 1990 study and subsequent replications. The 20-30 percent reduction in intraocular pressure following topical CBG administration is comparable to clinically used brimonidine. However, randomized trials in humans are lacking, so CBG does not replace approved glaucoma therapy. This is a direction for future research.

In neurodegenerative diseases, CBG has been shown to have neuroprotective effects in models of Huntington's disease (Valdeolivas et al., Neurotherapeutics, 2015). It protects striatal neurons from 3-nitropropionic acid toxicity. Similar effects have been observed in models of amyotrophic lateral sclerosis (ALS) and Parkinson's disease. This is early research, but it opens up new research areas.

In metabolism, CBG may increase appetite without any psychoactive effects, which distinguishes it from THC. A 2016 study in rats showed that CBG at a dose of 120-240 mg/kg increased food intake by 28 percent. This is a potential therapeutic approach for patients with oncological cachexia and senile anorexia.

Citation capsule: In the study by Farha et al. (ACS Infectious Diseases 2020), CBG inhibited the growth of MRSA at a MIC of 2 micrograms/ml, a value comparable to vancomycin, and disrupted bacterial biofilm at non-bactericidal concentrations, indicating a unique two-step mechanism of action (ACS Infectious Diseases, 2020). This opens the door to research on CBG as an adjuvant to antibiotic therapy for resistant infections.

How does CBG differ from CBD in practice?

Although CBG and CBD have an identical molecular formula of C21H30O2 in their neutral form, their geometry, receptor profile, and subjective effects are distinctly different. Both are non-psychoactive, but 51 percent of CBG users in a 2021 survey reported improved concentration, and 66 percent of CBD users reported improved sleep (Cannabis and Cannabinoid Research, 2021).

CBD acts primarily indirectly: it modulates the 5-HT1A serotonin receptor (anti-anxiety effect), inhibits the FAAH enzyme (increases anandamide levels), and activates TRPV1 receptors (analgesic effect). Direct affinity for CB1 and CB2 is minimal. This explains why CBD at higher doses (300 mg and above) has anxiolytic and anticonvulsant effects.

CBG acts directly: it activates CB1 and CB2 as a partial agonist, binds strongly to alpha-2 adrenergic receptors, and influences TRPV1 and PPAR-gamma. The subjective effect is more of a "focus without drowsiness" than a "relaxation." Therefore, CBG is gaining popularity among mentally active individuals, athletes seeking muscle relaxation, and patients with digestive disorders.

Differences in availability and market price

CBD is significantly cheaper to produce, as hemp plants contain 10-20 percent CBD by weight. 10 percent CBD oil in Poland costs 90-150 PLN per 10 ml. CBG occurs naturally in amounts below 1 percent, making extraction 10-20 times more difficult. Therefore, 10-15 percent CBG oil costs 200-300 PLN per 10 ml. The price difference stems from the difficulty of obtaining the raw material, not from greater efficacy.

In 2024, CBG availability in Poland increased significantly. "CBG-dominant" varieties with 10-15 percent CBG appeared in major EU extractors. This reduced the unit cost by approximately 30 percent compared to 2022. Further price declines are expected as CBG-dominant genetics become standard in hemp breeding (Hemp Facts, 2024).

When to choose CBG and when to choose CBD?

CBG makes sense if you're looking for: improved concentration without drowsiness, muscle relaxation, support for gut health, potential topical antibacterial effects, or a "morning" cannabinoid profile. A 10-15% CBG oil at 15-30 mg doses in the morning works well for mentally active individuals, programmers, writers, and managers.

CBD makes sense if you're looking for: sleep support, anxiety and stress reduction, improved recovery after exercise, and anti-inflammatory effects on the skin. Broad-spectrum CBD oil at 5-10% doses of 20-50 mg daily is the most common protocol. CBD is also a better choice for people with clinical anxiety because it has more human RCT data.

The most common solution is a combination. Broad-spectrum CBD oil in the morning and evening, plus 15 percent CBG oil around 8-10 a.m. for "focus." This setup takes advantage of the entourage effect, covering the entire day and providing flexibility. A 2023 Project CBD study shows that 62 percent of regular users choose a combination of different cannabinoids (Project CBD, 2023).

From the Bucha editorial office: Over the past 18 months, we've observed that customers most often ask about CBG in two contexts: "I can't concentrate at work" and "I have gut problems, CBD isn't enough." These are distinctly different profiles than the classic CBD queries ("I can't sleep, I'm stressed"). Therefore, in our store categorization, we've identified CBG as a separate segment, not as a subcategory of CBD. This decision reflects real-world consumer behavior.

How to properly dose CBG sublingually?

A reasonable CBG dosage starts at 10-15 mg per day and ends in the 25-50 mg range for most users. An observational study by Russo et al. (Cannabis and Cannabinoid Research 2022) found that the average effective dose among regular CBG users was 28 mg per day, most often divided into two doses. Higher doses (above 100 mg) have been used in animal models and are not routinely recommended in humans.

The "start low, go slow" principle applies even more strongly to CBG than to CBD. CBG has a different dose-response profile: too high a dose can cause agitation, anxiety, or increased blood pressure due to 5-HT1A antagonism. Therefore, a reasonable protocol is: 10 mg once daily for 5-7 days, then 10 mg in the morning and 10 mg at noon for another 5-7 days, with a target of 15-20 mg twice daily.

The sublingual form is the gold standard. You hold CBG oil drops under your tongue for 60-90 seconds before swallowing. This bypasses the first pass through the liver and provides a bioavailability of 13-19 percent, compared to 6-10 percent for capsules and gummies. The effect begins in 15-45 minutes, peaks in 60-90 minutes, and the overall duration of action is 4-6 hours.

How to convert drops to milligrams?

A standard drop of oil has a volume of approximately 0.05 ml. At a 5 percent CBG oil concentration, one drop contains approximately 2.5 mg of CBG. At 10 percent, it's about 5 mg, and at 15 percent, it's about 7.5 mg. To achieve a dose of 15 mg of CBG, you'll need 6 drops of 5 percent oil, 3 drops of 10 percent oil, or 2 drops of 15 percent oil.

In practice, the choice of concentration depends on the target dose and convenience. For starting doses of 10-15 mg per day, 5 percent CBG oil is sufficient. For advanced users (25-50 mg per day), 10 or 15 percent oil is better, as the smaller droplet volume means less strain on the palate and faster sublingual absorption.

Combining CBG with CBD in One Protocol

The most common combination is 5-10% broad-spectrum CBD oil as a daily base, plus 15% CBG oil as a morning supplement. Doses: 20-40 mg of CBD total daily, plus 15-20 mg of CBG in the morning. This combination balances the effects of both cannabinoids without overlapping their effects. CBD provides a base of relaxation and anti-inflammatory effects, while CBG adds focus and digestive support.

There's also an alternative: full-spectrum oil, which naturally contains CBD, CBG, CBC, CBN, and terpenes. This oil achieves the entourage effect without the need to combine two products. The drawback is the lack of precise CBG dosage control, as the proportions of cannabinoids in full-spectrum oil are inherently variable depending on the cannabis strain and batch.

Drug interactions, CYP450

Like CBD, CBG inhibits cytochrome P450 enzymes, primarily CYP3A4 and CYP2C9. This means it can affect the metabolism of many drugs, including warfarin, statins, antiepileptic drugs, some antidepressants, and calcineurin inhibitors (PMC, 2019). If you are taking medications metabolized by CYP3A4, consult your doctor or pharmacist before supplementing with CBG.

A good rule of thumb: separate CBG and medications over time. Take the cannabinoid at least two hours before or after the medication. This doesn't eliminate the interaction, but it does minimize it. Monitor the therapeutic effects of the medications (e.g., INR in warfarin patients, antiepileptic drug levels) and report any changes in their effects to your doctor after starting CBG.

Special caution is advised with: warfarin and other anticoagulants (risk of bleeding), antiepileptic drugs (clobazam, valproate), and post-transplant immunosuppressants (tacrolimus, cyclosporine). Never combine CBG with medications without your doctor's knowledge if you are on long-term therapy.

What is the legal status of CBG in Poland and the EU in 2026?

CBG is not on the Polish list of controlled substances or on the EU drug lists, and its content in the product is not limited (Journal of Laws 2005 No. 179 item 1485). The legality of CBG oil depends solely on the THC content, which must be below 0.3 percent in accordance with EU Regulation 2021/2115 on hemp.

In Poland, CBG products are primarily sold as cosmetics (for skin application) or "collectibles." They are not registered as dietary supplements or medicines. This is due to the EU's status as a "novel food," which has been lacking EFSA authorization since 2019. The process is ongoing, but currently, producers must adjust their labeling.

Like CBD, CBG is legal in other EU countries, though with local variations. In France, restrictions on the list of cannabinoids were in place until 2022, but following the EU General Court's ruling in the Kanavape case, producers were given full freedom to trade CBD and CBG throughout the EU, provided they comply with the 0.3% THC limit. In Germany and the Netherlands, CBG has a status similar to that of Poland.

What is allowed and what is not allowed in marketing communications

You are allowed to: describe CBG products as supporting wellness, relaxation, concentration, and digestive comfort (use the language of "support," not "treatment"). You are allowed to: publish chemical composition, scientific studies, and laboratory data. You are allowed to: sell in-store and online. You are allowed to: carry it in carry-on luggage domestically and in EU countries with a similar THC limit.

You may not: represent CBG products as medicine or use medical claims ("treats IBD," "cures glaucoma"). You may not: sell products with THC above 0.3 percent. You may not: transport CBG to countries with restrictive drug laws (e.g., Hong Kong, United Arab Emirates, Japan) without first verifying the regulations.

COA Certificates and Trusted Supplier

A Certificate of Analysis (COA) from an independent laboratory is essential when purchasing CBG oil. The COA should include: cannabinoid analysis (CBD, CBG, CBN, CBC, THC), heavy metal analysis, pesticide analysis, residual solvent analysis, and microbiology analysis. Without a COA, you don't know what you're actually buying. Manufacturers without a COA are a red flag.

At Bucha, every CBG oil has a COA available for viewing on the product page or upon request. This is a standard we've built over five years of operation. If a manufacturer refuses to provide a COA, it's the best reason to avoid purchasing. There are still products on the market with CBG content significantly lower than what's declared on the label.

Bucha data Q1 2026: In our CBG oil category, 78 percent of orders are for concentrations of 10-15 percent, 15 percent of customers choose 5 percent as a starting point, and only 7 percent go for higher concentrations above 15 percent. The average order value for CBG is 185 PLN, compared to 120 PLN for CBD. CBG customers are more loyal, with 64 percent returning for a repeat purchase within 60 days, compared to 48 percent for CBD.

Why is CBG more expensive than CBD?

The price of 10-15 percent CBG oil is on average 2-3 times higher than CBD oil of the same strength, which is mainly due to the low CBG content in the plant (usually below 1 percent) and the higher cost of extraction. CBG oil 15 percent costs around 240 PLN per 10 ml in Poland, while CBD oil 10 percent can be purchased for 99 PLN (Hemp Facts, 2024). The price difference reflects the difficulty of the raw material, not the therapeutic value.

CBG extraction requires precise harvest timing. The plant must be harvested before the CBGA synthase enzymes consume it. This means earlier harvesting (3-4 weeks before full maturity) and lower biomass per hectare. Therefore, CBG yields from classic varieties are 50-70 percent lower than CBD yields. CBG-dominant varieties allow for harvesting at the normal harvest time, but the genetics themselves are more expensive to license.

Until 2024, the CBG market in Europe was dominated by a handful of producers. Competition was limited, which kept margins high. Now, with the emergence of more CBG-dominant strains and extractors specializing in this cannabinoid, prices are beginning to decline. We anticipate a gradual convergence of CBG prices with CBD over the next 3-5 years, but never complete parity.

What influences the quality of CBG oil?

Key factors: 1) origin of the raw material (organic vs conventional hemp), 2) extraction method (supercritical CO2 vs ethanol vs petrochemical), 3) product purification (short path distillation, chromatography), 4) oil carrier (MCT from coconut vs hemp oil vs grape seed oil), 5) storage and packaging (amber glass, cool place).

The highest quality is achieved through supercritical CO2 extraction from organic hemp, short-path distillation, and MCT oil. This process removes unwanted components (chlorophyll, waxes) and concentrates cannabinoids. Ethanol extraction is cheaper but requires careful purification to remove residual solvent. Petrochemical extractions (hexane, butane) are inexpensive but pose a risk of product contamination.

Full-spectrum vs broad-spectrum vs CBG isolate

Full-spectrum CBG contains the full profile of the plant's cannabinoids and terpenes, including trace amounts of THC (less than 0.3 percent). Broad-spectrum CBG is purified from THC while retaining other cannabinoids and terpenes. CBG isolate is 99 percent pure cannabinoids, free of other compounds. While the price differences are minor, the differences in effect are significant.

A 2015 study showed that full-spectrum extracts with the same primary cannabinoid content have a stronger effect than isolates, thanks to the entourage effect. The difference was 25-40 percent in anti-inflammatory models. This is why most users choose full-spectrum or broad-spectrum. Isolates are primarily useful in clinical trials, where the effect of a specific molecule needs to be isolated.

What are the side effects and contraindications of CBG?

CBG is generally well tolerated, with a safety profile similar to CBD. In an observational study of 127 CBG users, the most common side effects were dry mouth (16.5 percent), drowsiness (15 percent), and increased appetite (12 percent) (Cannabis and Cannabinoid Research, 2021). Serious side effects are rare and usually associated with very high doses.

Potential side effects of CBG include: dry mouth and eyes (due to cholinergic modulation), slight reduction in blood pressure (at higher doses, via alpha-2), drowsiness or agitation (depending on dose and individual sensitivity), and mild digestive upset (diarrhea, nausea in about 5 percent of users in observational studies).

Very rare side effects include: changes in appetite (both increases and decreases), headaches (in a small percentage of users), and feelings of anxiety at very high doses (above 100 mg). Most side effects subside upon lowering the dose or are transient after a few days of regular use as the body adapts to the new cannabinoid.

Who should avoid CBG?

Absolute contraindications include: pregnancy and breastfeeding (no safety studies for the fetus and infant, potential for CBG to cross the placental barrier), severe liver disease (CBG is metabolized by CYP450, risk of accumulation), and children under 18 years of age without medical supervision. All these groups require caution and medical consultation.

Relative contraindications include: patients with low blood pressure (hypotension may worsen), individuals with severe psychiatric disorders (schizophrenia, bipolar disorder; CBG may modulate neurochemical balance), and patients taking medications metabolized by CYP3A4 (see the interactions section above). In these groups, the decision to use CBG should be made on an individual basis.

Is CBG safe to use long term?

There are no randomized, placebo-controlled studies of CBG in humans longer than 6 months. Observational studies have covered periods up to 2 years and have not shown serious long-term side effects. However, this does not equate to full safety validation. Periodic breaks (e.g., 2 weeks every 3 months) and monitoring of health parameters are recommended for any supplement.

A practical recommendation: use CBG for 8-12 weeks, then take a 2-week break and assess whether the effects have persisted. If not, resume supplementation. If so, consider whether further regularity is necessary. This cyclical approach minimizes the risk of tolerance (although CBG does not exhibit classic tolerance like THC) and allows for the assessment of the cannabinoid's true effectiveness.

Patients taking CBG are monitored long-term for liver function (ALT, AST, GGT, every 6-12 months), blood pressure (at higher doses), and body weight (CBG may increase appetite). Standard annual medical checkups cover most of these parameters, so additional visits are usually unnecessary.

Frequently asked questions

What is CBG and how is it different from CBD?

CBG (cannabigerol) is a non-psychoactive cannabinoid considered the mother of all cannabinoids, as its acid form, CBGA, is the biochemical precursor to CBDA, THCA, and CBCA. Unlike CBD, which primarily acts indirectly through the 5-HT1A receptor and FAAH inhibition, CBG binds directly to CB1 and CB2 as a partial agonist and activates the alpha-2 adrenergic receptor (Cascio et al., British Journal of Pharmacology, 2010). In a mature cannabis plant, the typical CBG content is less than 1 percent.

Does CBG have psychoactive effects?

No. CBG does not cause a high or intoxicating effect because it acts as a very weak partial agonist at the CB1 receptor and partially antagonizes the effects of THC. Report WHO Expert Committee on Drug Dependence (41st Session, 2018) confirms the safe profile of non-psychoactive hemp cannabinoids. CBG does not impair driving or cause the tolerance typical of THC.

What is the dosage of CBG?

Preclinical and observational studies suggest a range of 10-50 mg of CBG per day in adults. A reasonable start is 10-15 mg once daily sublingually, with titration every 5-7 days by 10 mg. In an observational study, users reported benefits at an average dose of 25-30 mg per day (Cannabis and Cannabinoid Research, 2021). Higher doses (100-200 mg) have been used in a mouse model of IBD and are not routinely recommended in humans.

Does CBG help with glaucoma?

Potentially yes, provided it is applied topically. Colasanti's study (Journal of Ocular Pharmacology, 1990) showed that topically administered CBG lowers intraocular pressure in rabbits. The mechanism involves activation of the alpha-2 adrenergic receptor, the same receptor targeted by brimonidine eye drops. Randomized trials in humans are lacking, so CBG does not replace any registered glaucoma treatment. Consultation with an ophthalmologist is mandatory.

Can CBG be combined with CBD?

Yes, and it's often beneficial. CBG and CBD work on partially complementary pathways: CBD modulates 5-HT1A and FAAH, CBG activates CB1, CB2, and alpha-2. Russo's work in the British Journal of Pharmacology (PMC, BJP, 2011) described the entourage effect. In practice, broad-spectrum and full-spectrum oils contain both compounds naturally, in proportions depending on the cannabis variety.

Is CBG legal in Poland?

Yes, CBG itself is not a controlled substance in Poland or the EU. The legality of a product depends on its THC content: CBG oils with THC below 0.3% comply with EU Regulation 2021/2115 on hemp. Since 2019, EFSA has considered cannabinoid extracts a novel food, so CBG supplements require compliance with food regulations. Buy from trusted suppliers with COA certificates.

Does CBG have antibacterial properties?

Yes, and against resistant strains. The study by Farha et al. (ACS Infectious Diseases, 2020) showed that CBG inhibited the growth of methicillin-resistant Staphylococcus aureus (MRSA) at concentrations comparable to vancomycin in vitro. CBG disrupted bacterial biofilms and was effective in a murine infection model. These data are preclinical; CBG does not replace antibiotics in the treatment of bacterial infections in humans.

What do studies say about CBG in inflammatory bowel disease?

The work of Borrelli et al. (Biochemical Pharmacology, 2013) showed that CBG reduced inflammation in a mouse model of DNBS-induced colitis by approximately 50 percent compared with the control group. The mechanism involves inhibition of iNOS synthase, reduction of IL-1beta, and modulation of CB2. Observational data in humans suggest subjective improvement in IBS and IBD symptoms, but randomized trials in patients are still ongoing.

This article is for informational and educational purposes only and does not constitute medical advice. Consult your doctor before using cannabis or CBG for therapeutic purposes, especially if you are taking other medications, pregnant, or breastfeeding.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: September 27, 2025
Last update: April 23, 2026